The dorsolateral prefrontal cortex (dlpfc) is strongly implicated in the pathogenesis of schizophrenia (SCZ) and bipolar disorder (BPD) and, within this region, abnormalities in glutamatergic neurotransmission and synaptic function have been described. Proteins associated with these functions are enriched in membrane microdomains (MM). In the current study, we used two complementary proteomic methods, two-dimensional difference gel electrophoresis and one-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis followed by reverse phase-liquid chromatography-tandem mass spectrometry (RP-LC-MS/MS) (gel separation liquid chromatography-tandem mass spectrometry (GeLC-MS/MS)) to assess protein expression in MM in pooled samples of dlpfc from SCZ, BPD and control cases (n = 10 per group) from the Stanley Foundation Brain series. We identified 16 proteins altered in one/both disorders using proteomic methods. We selected three proteins with roles in synaptic function (syntaxin-binding protein 1 (STXBP1), brain abundant membrane-attached signal protein 1 (BASP1) and limbic system-associated membrane protein (LAMP)) for validation by western blotting. This revealed significantly increased expression of these proteins in SCZ (STXBP1 (24% difference; P < 0.001), BASP1 (40% difference; P < 0.05) and LAMP (22% difference; P < 0.01)) and BPD (STXBP1 (31% difference; P < 0.001), BASP1 (23% difference; P < 0.01) and LAMP (20% difference; P < 0.01)) in the Stanley brain series (n = 20 per group). Further validation in dlpfc from the Harvard brain subseries (n = 10 per group) confirmed increased protein expression in SCZ of STXBP1 (18% difference; P < 0.0001), BASP1 (14% difference; P < 0.0001) but not LAMP (20% difference; P = 0.14). No significant differences in STXBP1, BASP1 or LAMP protein expression in BPD dlpfc were observed. This study, through proteomic assessments of MM in dlpfc and validation in two brain series, strongly implicates LAMP, STXBP1 and BASP1 in SCZ and supports the view of a neuritic and synaptic dysfunction in the neuropathology of SCZ.
Introduction
There is converging evidence that a fundamental pathology of schizophrenia (SCZ) and bipolar disorder (BPD) involves a dysfunction of synaptic transmission, neural connectivity and GABA-ergic 1 and glutamatergic activity. 2, 3 Dorsolateral prefrontal cortex (dlpfc) 4, 5 is implicated in SCZ 6 and in BPD 7 with cytoarchitectural studies of this region in SCZ reporting an array of alterations in cortical neuronal density 8, 9 and size, 10 glial cell density 10 and dendritic spine density 11 in the dlpfc in these disorders (for review see 6 Harrison and Weinberger, 2005). Functional imaging and neurochemical and cytoarchitectural studies reveal patterns of aberrant activation and alterations to synaptic transmission, in particular to GABA-ergic 12 and glutamatergic 13 neurotransmission in the schizophrenic brain. These findings strongly suggest that changes in synaptic transmission and neural connectivity are a core feature of SCZ.
Studies by Beasley et al. 14 and others 15, 16 have investigated the proteome of the anterior cingulate cortex and dlpfc in the SCZ and BPD brain and revealed prominent synaptic and metabolic abnormalities in both disorders. Most recently, our group undertook a proteomic analysis of the dlpfc 17 and further characterized the synaptic and synaptic-associated pathology in SCZ by demonstrating alterations in the septin family of proteins, protein kinase C and casein kinase in neurons 1 (PACSIN1) and neurofilament triplet L in SCZ. These findings complement the literature reporting changes in protein kinase C 18 and synaptic proteins 19 in SCZ, although some negative studies have been published. 6, 20 These findings, together with the known functions of candidate susceptibility genes, 6 add to a growing body of evidence that describes and characterizes the synaptic and N-methyl D-aspartate receptor dysfunction in SCZ. In the current investigation, our aim was to focus in more detail on these functions. As proteomic studies of whole brain tissue are biased towards the identification of the more abundant proteins, and exclude many of the proteins that are of interest to us, we chose to use enrichment techniques that enable the targeting of the less abundant and more functionally specific subproteomes. 21 Membrane microdomains (MM) are specialized structures within the plasma membrane that have an altered lipid composition, links to the cytoskeleton and, more importantly, contain a vast pool of neurotransmitter receptors, trafficking proteins and signal transduction proteins in the brain. 22 In addition, they contain soluble NSF attachment receptor (SNARE) proteins and complexes, as well as important elements in the control of regulated exocytosis. 23 Proteins such as N-methyl D-aspartate receptors, GABA receptors and glutamate transporters are present in MM and are implicated in SCZ pathology. 22 Previous proteomic studies have identified proteins associated with MM in a variety of cell types, [24] [25] [26] [27] [28] with one study identifying MM proteins within chemical synapses from the rat brain. 29 No expression study of MM proteins in the human cortex proteome has yet been carried out, although some preliminary work has been undertaken. 30 The aim of this study was to assess differential protein expression of MM-associated proteins in pooled grey matter dlpfc samples from control, SCZ and BPD subjects. Our strategy involved the use of two complementary proteomic methods, two-dimensional difference gel electrophoresis (2D DIGE) and onedimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis (1D SDS-PAGE), followed by RP-LC-MS/MS (GeLC-MS/MS) on pooled samples from each group to first identify interesting candidate proteins and then to validate the findings, first, in the same brain series and then in another independent brain series. Our validation was focussed on proteins involved in neuroplasticity that showed expression changes in both SCZ and in BPD. Manual of Mental Disorders (DSM-IV) criteria. Diagnoses for SCZ were made according to Feighner's criteria and according to the DSM-IV criteria for BPD in the Harvard series. For both brain series, exposure to antipsychotic drugs, presented as chlorpromazine (CPZE) equivalents, was estimated from knowledge of prescribed antipsychotic drugs at time of death, chart note review and discussion with family members regarding compliance. CPZE equivalents represent the approximate dose equivalent to 100 mg of CPZE (relative potency), and are used as an indicator of relative antipsychotic potencies of antipsychotic drugs.
Materials and methods

Samples
Due to the limited availability of the amounts of tissue samples, we were obliged to pool samples from the 10/10/10 Stanley brain series into one representative pooled sample for each group to obtain sufficient MM protein for both proteomic analyses. From our Stanley series, a 10/10/10 series of the best-matched brains for the shortest post-mortem delay, highest pH, age and gender was selected for the pooled study. For our validation study, an extended 20/20/20 series from the Stanley series and a 10/10/10 series from the Harvard brain series were selected. See Table 1 for summaries relating to age, gender, post-mortem delay, tissue pH, brain side, brain weight and cause of death for each of these subseries.
Study design
Step 1: identification of 'candidate' proteins. Due to the limited availability of the amounts of tissue samples, we were obliged to pool samples from the 10/10/10 Stanley brain series into one representative pooled sample for each group to obtain sufficient MM protein for both proteomic analyses. Two complementary proteomic analyses (2D DIGE and GeLC-MS/MS) were viewed as exploratory and as representing a method of identifying 'candidate' proteins of interest. 'Candidate' proteins were defined as proteins that demonstrated altered expression in the same direction for both 2D DIGE and GeLC-MS/MS in SCZ and/or BPD.
Step 2: validation study. It was decided that validation experiments should focus on the most interesting of these proteins. Building on our findings 14, 17 and those of others 15, 16 of synaptic changes in both SCZ and BPD, selection criteria for these were that (i) proteins demonstrated altered expression in both BPD and SCZ, and (ii) proteins were involved in synaptic and synaptic plasticityassociated functions. Proteins that met these criteria would be validated using western blotting in individual cases in an extended Stanley Foundation Array series with the validation then extended to the Harvard Brain Tissue Resource Centre McLean 66 brain series.
Preparation of the total membrane fraction from dlpfc Total membrane fractions were isolated as previously described 31 with some minor modifications as detailed below. Grey matter dlpfc (50 mg) was dissected from each case and pooled within the necessary group (CON/SCZ/BPD) to form three pooled samples of 500 mg dlpfc for CON, SCZ and BPD groups. Grey matter dlpfc (500 mg) for each group was homogenized in 5 ml of 150 mM NaCl, 20 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , 1 mM EDTA, and 20% (vol/vol) glycerol, pH 7.4. Homogenization was achieved by 30 passes of a Dounce homogenizer equipped with a glass pestle, followed by sonication (30% maximum power pulsed for 30% of the time) for 5 Â 1-min periods with a 1-min cooling period between each round of sonication. After sonication, the samples were centrifuged at 5000 g at 4 1C for 20 min, following which the supernatant was removed, made up to the correct volume with homogenization buffer to fit 4 ml Sorvall tubes and centrifuged for 90 min at 4 1C at 100 000 g. The resultant membrane pellet was resuspended in 4 ml of Tris-buffered saline (1 Â TBS) in a Sorvall tube.
Isolation of the detergent-resistant membrane fraction
The resuspended membrane pellet was centrifuged for 90 min at 4 1C at 100 000 g, and the pellet was resuspended in 2 ml of lysis buffer (1 Â TBS containing 2 m EDTA and 2% (vol/vol) Triton X-100). The sample was sonicated as described above and then mixed at 4 1C for 90 min on a fixed-speed, fixed-angle rotator. After mixing, an aliquot (0.5 ml) of the solubilized membranes was diluted with an equal volume of 80% (wt/vol) sucrose in TBS containing 2 mM EDTA, 2% (vol/vol) Triton X-100 and 1:100 dilution of a protease inhibitor cocktail (Sigma-Aldrich, Dublin, Ireland). This sample was pipetted in as a 40% part (bottom-1 ml) of a discontinuous sucrose gradient consisting of 30% (wt/vol) sucrose (middle-2 ml) and 5% (wt/vol) sucrose (top-1 ml), both solutions made up in TBS containing 2 mM EDTA and 1:100 protease inhibitor cocktail. The sucrose gradient was centrifuged at 100 000 g for 24 h at 4 1C in a Sorvall RC-M120EX ultracentrifuge. Ten fractions (400 ml) were harvested from the top to the bottom of the centrifuge tube at 4 1C and precipitated with 80% (v/v) acetone as described previously. 32 The resulting pellets from the 10 Â 400 ml fractions were resuspended in urea/thiourea buffer (7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulphonate, 30 mM Tris/HCl (pH 6.8)) and assayed for protein concentration using the Bradford assay. For MS analysis, fractions 3-6 (detergent-resistant membrane pellets B30 mg) were pooled for our two proteomic approaches (see next section). Determination of flotillin-1 and transferrin receptor distribution The methods for SDS-PAGE and western blotting were undertaken as described previously with the following modifications. 33 For western blot analysis, gels were transferred to nitrocellulose membranes and probed with specific antibodies as described previously. 34 Mouse monoclonal antibodies to flotillin-1 (clone 18, 1:500 dilution) and transferrin receptor (anti-CD71, 1:200 dilution) were purchased from BD Biosciences (Oxford, UK) and Chemicon (Hampshire, UK) respectively.
Step 1 2D DIGE. Pooled protein samples (30 mg) from the three disease groups were run in triplicate in a two CyDye DIGE experiment. An internal standard was prepared with equal fractions of all pooled samples and bulk-labelled with 240 pmol Cy3 per 30 mg of protein. A 30 mg aliquot of each of the nine samples was labelled with 240 pmol of Cy5, according to the manufacturer's protocol. After labelling, Cy3-and Cy5-labelled proteins were combined and diluted 1:1 with dilution buffer (9.5 M urea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate, 2% dithiothreitol, 1.6% Pharmalyte, pH 3-10) and loaded onto pH 3-10 24 cm immobilized pH gradient strips (GE HealthCare, Cork, Ireland) using in-gel rehydration as previously described. 35 Strips were left to rehydrate overnight and subsequently focussed for 75 000 Vh at 20 1C. Following the IEF dimension, strips were equilibrated in 6 M urea containing 30% (w/v) glycerol, 2% (w/v) SDS and 0.01% (w/v) Bromophenol blue, with the addition of 1% dithiothreitol for 15 min. Strips were then incubated for a second 15 min in the same buffer without dithiothreitol, but with the addition of 4.8% (w/v) iodoacetamide. The 2D PAGE was performed according to standard protocols described by Focking et al. 36 Seconddimension SDS-PAGE was performed using 12% polyacrylamide gels run overnight at 20 mA per gel at 15 1C (Ettan-DALT System; GE Healthcare) and was terminated when the bromophenol dye front had migrated off the end of the gels.
2D DIGE image analysis. Scanning of the gels with CyDye-labelled proteins was performed as described previously 36 on a Typhoon 9410 Image scanner (Amersham Biosciences, Amersham, UK). Using the software package DeCyder v6.5, intra-gel spot detection and quantification was performed using the differential in-gel analysis mode whereas images from different gels were matched using the biological variance analysis mode. Protein spots with an average expression level X1.2-fold change (threshold based on recent publications 17, 37 ) across triplicate gels were defined as being altered.
Spot picking and processing. Preparative 2D gels (4 Â 100 mg preparative gels) were run as described above and fixed for a minimum of 1 h in a methanol/ acetic acid/water solution (4:1:5 v/v/v). The resulting 2D protein profiles were visualized using the PlusOne silver staining kit (Amersham Biosciences) with slight modifications to ensure compatibility with subsequent MS analysis. 38 Spots of interest were picked using a manual spot picker and pooled from the four preparative gels. Spot plugs were destained 39 and proteins were digested with trypsin as previously described. 35 LC-MS/MS. Tryptic peptides of the selected 2D gel spots were analysed using Thermo linear quadrupole ion trap mass spectrometer as described previously. 36 All MS/MS spectra were sequence database searched using TurboSEQUEST. The MS/MS spectra were searched and identified against the non-redundant International Protein Index database (v.3.14).
GeLC-MS/MS. The MM-enriched samples were reduced, solubilized in 2 Â Laemlli buffer and separated on 4-20% gradient precast acrylamide gels (7 cm) (Pierce, MSC Ltd., Dublin, Ireland). Gels were stained with colloidal Coomassie Brilliant Blue G-250 (Biorad, Hemel-Hampstead, Herts, UK) and each lane was cut into 10 bands (6 mm Â 6 mm) and digested in-gel with trypsin according to the method of Shevchenko et al. 39, 40 The resulting mixtures were resuspended in 1% formic acid and analysed by nano-electrospray liquid chromatography mass spectrometry. A high-performance liquid chromatography instrument (Dionex, UK) was interfaced with a Thermo linear quadrupole ion trap mass spectrometer (ThermoFinnigan, California, USA). Chromatography buffer solutions (buffer A, 5% acetonitrile and 0.1% formic acid; buffer B, 80% acetonitrile and 0.1% formic acid) were used to deliver a 60 min gradient (35 min to 45% buffer B, 10 min to 90%, hold 10 min, 3 min to 5%, hold for 15 min). A flow rate of 2 ml min À1 was used at the electrospray source. Spectra were searched using the SEQUEST algorithm as described previously against the International Protein Index database (v.3.14). The probability-based evaluation program, Protein Prophet, was used for filtering identifications. 41 Analysis of proteomic data.
2D DIGE: decyder analysis Average spot intensity values per spot were calculated across the triplicate gels for each pooled group and spots that demonstrated an average spot intensity X1.2-fold change between the three groups were defined as altered in expression. These spots were excised from preparative gels and identified by tandem mass spectrometry.
GeLC-MS/MS: ion spectral count For crude quantification at the peptide level, spectral counts (the number of tandem MS events leading to a productive protein identification) for each peptide spectrum were summed to give a total peptide count for each protein. The sum of peptide counts for each disease group was calculated and tabulated as fold changes. Proteins that (i) have an ion spectral count of greater than 5 in at least one of the two groups (that is CON vs BPD or CON vs SCZ) and (ii) a fold change of greater than 1.2 were defined as altered for the purpose of this investigation.
Step 2
Validation of proteins using western blotting. The levels of these 'candidate' proteins outlined in the Study design section were quantified by western blotting in the extended 20 CON/20 SCZ/20 BPD brain series from the Stanley and, separately, the 10/ 10/10 Harvard brain collection. All were individually analysed in triplicate using whole-cell lysates as described previously. 34 Equal amounts of denatured homogenates (30 mg per lane) were loaded and resolved on 10% SDS-PAGE gels as described before. 34 Gels were blotted onto nitrocellulose membranes, blocked and incubated overnight at 4 1C with polyclonal antibodies against syntaxin-binding protein 1 (STXBP1) (1:1000, Synaptic Systems, Goettingen, Germany), brain abundant membrane-attached signal protein 1 (BASP1) (1:750, Abcam, Cambridge, UK) or monoclonal limbic system-associated membrane protein (LAMP) (1:500, a kind gift from Dr Pat Levitt, Vanderbilt University, Tennessee), followed by incubation with the appropriate species-specific horse radish peroxidase-linked secondary antibody (1:2000 dilution, DAKO, Dublin, Ireland). Blots were incubated with ECL reagent (Amersham Biosciences), exposed to X-ray film and developed accordingly. The optical density of the protein bands was measured using Adobe Photoshop Image Acquisition Software. Band densities were normalized (i) against the optical density of the MemCode stained lane (total protein) for that sample (Pierce) and (ii) against an internal standard run on each gel (used to reduce gel-to-gel variation). The mean relative expression for all the three proteins was calculated.
Statistical analysis of western blotting data. Using the mean relative expression values from our western blotting analysis, analysis of variance (ANOVA) was run using diagnoses as factors. If ANOVA indicated a significant effect of diagnosis, post hoc analyses using the independent samples t-test of individual disease groups compared with controls were undertaken. Protein expression was deemed significantly different from control levels if the group mean differed from control mean group value at the 5% level. Post-mortem interval and brain pH were not significantly different between groups and were not included in the primary analysis. The effects of exposure to antipsychotic drugs, antidepressant drugs and mood stabilizers on LAMP, BASP1 and STXBP1 protein expression were assessed by (i) comparing protein levels among those patients (combined group of BPD and SCZ) exposed to these drugs, with those patients who were not exposed (Student's t-test). In addition, correlation analysis between protein expression data in the Stanley and Harvard brain series and the dose of prescribed neuroleptic drugs (CPZE equivalents), age, post-mortem interval and tissue pH was assessed. The effects on protein expression of gender in the patient and control sample, and death by suicide within the patient groups, were investigated (Student's t-test). The mean coefficient of variation was determined for candidate proteins in both brain series. To control for inter-gel variation, the mean covariance of the internal standards run on each gel was determined. All parametric statistical analyses were carried out in SPSS13 for Windows (SPSS). Deviations from normality were assessed using Shapiro-Wilks test and non-parametric analyses based on ranks (Kruskal-Wallis and Wilcoxon rank sum tests). The influence of outliers on our results was investigated using the Grubb's test.
Results
Flotillin-1 and transferrin receptor distribution
The position of the MM-associated proteins within the gradient was determined by immunoblotting for flotillin-1, a known MM marker 42, 43 and showed flotillin-1 to be enriched in fractions 3-6, representing the 5-30% interface of the sucrose gradient ( Figure 1 ). In keeping with previous reports that the transferrin receptor is present in non-detergent-resistant membrane fractions and is solubilized under the above conditions, 44 this receptor was found in the soluble membrane fractions only (fraction 10; Figure 1 ). Step 1 2D DIGE and MALDI-TOF. A total of 1496 individual spots were visualized across nine gels of MMassociated proteins (pH 3-10) (Figure 2) . Average values per spot were calculated across the triplicate gels for each pooled group and the spots that demonstrated a X1.2-fold change between the three groups were selected for identification. Of these 101 selected spots, 96 spots of interest were visually confirmed on the preparative gel and identified by mass spectrometry. Of these 96 spots, a total of 75 spots were identified as 51 proteins across disease groups using LC-MS/MS. Of the 75 spots characterized by our DIGE proteomic study, 51 proteins were identified and 56.8% (29 of 51) of these were previously associated with MM in brain tissue and/ or other cell types (see Supplementary Table S1 ).
Identities of all protein spots, their presence/absence in MM to date, their fold change, their theoretical isoelectric point (pI) and mass and the peptide sequences matched for each protein are shown in Supplementary Table S1 . A representative 2D spot map for MM proteins in the dfplc is outlined in Figure 2 . Supplementary Table S3 ). The proteins were rich in channel, vesicle and cytoskeletal proteins, and proteins involved in neurological processes. The proteins were monitored across the pooled sample series using spectral counts as a semiquantitative measure of protein abundance.
GeLC-MS/MS.
Selection of MM proteins for validation. As detailed in the Study design above, we applied a series of criteria to our selection of MM proteins for validation. This yielded 16 proteins that were defined as 'candidate' proteins on the basis of them showing a fold change in the same direction in disease groups by both proteomic methods. These proteins ( (Table 2 ). Three proteins were differentially expressed in both SCZ and BPD, and involved in synaptic-associated functions (italics in Table 2 ). These three proteins, LAMP, BASP1 and STXBP1, were selected for validation.
Validation by western blotting. For our validation, each protein migrated with a single band of the predicted molecular weight, that is, STXBP1 (66 kDa), BASP1 (40 kDa) and LAMP (60 kDa). Representative western blots for subjects in the three diagnostic groups are shown in Figure 3 . Quantitative variability within these gels was assessed by looking at the variation in the optical density for the internal standard across all gels. We found that covariance for the internal standard across the gels was < 5% in both brain series.
Protein expression in the Stanley array subseries. The quantitative results are illustrated in a scatter plot distribution in Figure 4 containing mean values and s.d. for each group. ANOVA revealed a significant effect of diagnosis for each of STXBP1 (F 2,56 = 9.41; P < 0.001), BASP1 (F 2,56 = 4.56; P < 0.01) and LAMP (F 2,56 = 5.77; P < 0.01) in the extended Stanley 20/20/ 20 series. Planned post hoc comparisons showed increased levels of expression in SCZ compared to controls for STXBP1 (1.41 ± 0.23; 24% difference; t 37 = 3.98; P < 0.001), BASP1 (1.95 ± 1.16; 40% difference; t 37 = 2.82; P < 0.05) and LAMP (1.35±0.30; 22% difference; t 37 = À2.76; P < 0.01) and increased expression of STXBP1 (1.55 ± 0.49; 31% difference; t 38 = À3.72; P < 0.001), BASP1 (1.57±0.67; 23% difference; t 38 = 3.35; P < 0.01) and LAMP (1.31 ± 0.33; 20% difference; t 38 = 2.82; P = P < 0.01) in BPD in the Stanley series. Table 2 .
Proteomics of MM-associated proteins in psychiatric disease in PFC ÁT Behan et al Protein expression in the Harvard subseries. Analysis of variance also revealed a significant effect of diagnosis for each of STXBP1 (F 2,27 = 6.79; P < 0.01) and BASP1 (F 2,27 = 9.99; P < 0.001). ANOVA did not reveal a significant effect of diagnosis for LAMP (F 2,27 = 1.31; P = 0.29) in the Harvard brain series. Planned post hoc comparisons showed increased levels of expression in SCZ for STXBP1 (1.05±0.05; 18% difference; t 18 = À5.12; P = P < 0.0001), BASP1 (1.10 ± 0.04; 14% difference; t 18 = À6.91; P = P < 0.0001) but not LAMP (2.06±0.48; 20% difference; t 18 = À1.53; P = 0.14). Planned post hoc comparisons showed no significant changes in the expression of STXBP1 (0.89 ± 0.16; 4% difference; t 18 = 0.60; P = 0.56), BASP1 (0.93±0.14; 2% difference; t 18 = 0.05; P = 0.82) and LAMP (2.11 ± 0.84; 22% difference; t 18 = 1.32; P = 0.20) in BPD.
Deviations from normality were detected (P < 0.01) for STXBP1/BASP1 in the Stanley series. However, deviations from normality do not necessarily invalidate the standard statistical procedures used in this paper (ANOVA, t-test). The robustness of our results using ANOVA and t-tests was confirmed using nonparametric analyses based on ranks (Kruskal-Wallis and Wilcoxon rank sum tests), which gave P-values on a similar scale (data not shown). Using the Grubb's test, no outliers were detected in the Harvard series while two outliers were detected (P < 0.01) in the Stanley series: one in the BPD group for STXBP1 (outlier value = 3.26) and one in the control group for BASP1 (outlier value = 2.32). The affected comparisons were re-analysed with these outliers excluded and this showed no significant impact upon the results (data not shown).
Potentially confounding effects of drugs and postmortem factors. In the Stanley subsample, there were no significant relationships between expression values for LAMP, STXBP1 or BASP1 and brain pH, post-mortem interval, gender or age. In the Stanley subsample, subjects exposed to neuroleptics, antidepressant drugs or mood stabilizers did not differ significantly in the protein expression levels of LAMP, BASP1 or STXBP1 compared to those patients who were not exposed. In the extended Stanley 20/20/20 subsample used for validating our proteomic findings, subjects (n = 40) that died from suicide (n = 12) did not differ significantly in the protein expression levels of LAMP (t 38 = 0.43; P = 0.78), BASP1 (t 38 = 1.11; P = 0.28) or STXBP1 (t 38 = 0.28; P = 0.67) compared to those subjects who died of natural causes (n = 28) within our psychiatric groups.
In the Harvard brain series, there were no significant relationships between expression values for LAMP, STXBP1 or BASP1 and brain pH, post-mortem interval, gender or age. In the Harvard subsample, subjects exposed to neuroleptic or to antidepressant drugs did not differ significantly in protein expression levels of LAMP, BASP1 or STXBP1 compared to those patients who were not exposed. Subjects exposed to mood stabilizers (n = 9) showed reduced expression of BASP1 (P = 0.01) and STXBP1 (P < 0.001) compared to those who were not (n = 7). In the Harvard 10/10/10 subsample, subjects (n = 20) that died from suicide (n = 6) did not differ significantly in the protein expression levels of LAMP (t 18 = À0.48; P = 0.64), BASP1 (t 18 = 0.77; P = 0.45) or STXBP1 (t 18 = 0.28; P = 0.78) compared to those subjects who died of natural causes (n = 14) within our psychiatric groups. There was no information available on four Harvard subjects from the disease groups. No significant correlations were observed between neuroleptic drug exposure, expressed as CPZEs and protein expression for LAMP, BASP1 and STXBP1 in the Stanley subsample series. Overall, there was no correlation between the levels of the three proteins in the Stanley series while, in the complete Harvard series, levels of STXBP1 and BASP1 protein expression correlated positively with one another (r = 0.93; P < 0.0001). Within individual disease groups for the Harvard series, STXBP1 and BASP1 expression correlated quite strongly with one another within the SCZ (r = 0.93; P < 0.001) and BPD (r = 0.90; Figure 3 Representative western blots demonstrating banding patterns for STXBP1, BASP1 and LAMP proteins in the dlpfc. Each blot is representative of n = 3 experiments and molecular weight is demarcated in kDa according to the molecular weight marker. All blots were normalized prior to quantitative comparisons. BASP1, brain abundant membrane-attached signal protein 1; BPD, bipolar disorder; CON, control; dlpfc, dorsolateral prefrontal cortex; LAMP, limbic system-associated membrane protein; SCZ, schizophrenia; STXBP1, syntaxin-binding protein 1.
P < 0.0001) groups. This correlation was also observed for STXBP1 and BASP1 within the SCZ group (r = 0.51; P < 0.05) in the Stanley series.
Discussion
Studies to date suggest that MM are necessary for (i) synaptic vesicle release and (ii) the recruitment of functionally linked proteins that underlie neurotransmitter vesicle dynamics and exocytosis. Synaptic dysfunction in SCZ is described, 19 but as yet is incompletely characterized. Our primary aim in the current investigation was to investigate synaptic function and neuronal plasticity in SCZ and BPD. For this reason, we undertook a proteomic analysis of SCZ and BPD disorder dlpfc tissue samples enriched with MM. We then undertook detailed validation experiments to confirm the protein changes in whole tissue samples. Our strongest findings in this study were for STXBP1 and BASP1 changes in SCZ and less strong for STXBP1 and BASP1 changes in BPD and for LAMP changes in both SCZ and BPD. Our findings provide novel insights into the neuropathology of these disorders and implicate synaptic and neuritic abnormalities in these disorders.
STXBP1, a known MM protein, 23 was significantly increased in SCZ in the Stanley and Harvard brain series. STXBP1 was also significantly increased in BPD in the Stanley subsample, but not altered in BPD in the Harvard brain series. STXBP1 is a presynaptic protein that binds to the closed conformation of syntaxin and thus inhibits its assembly into the SNARE complex. 53 Release from STXBP1 and activation of the open conformation of syntaxin is key to Figure 4 Protein expression changes of STXBP1 (a and b), BASP1(c and d) and LAMP (e and f) in the Stanley and Harvard series (10 CON/10 SCZ/10 BPD). *P < 0.05; **P < 0.01, ***P < 0.0001. P-values were identified by analysis of variance using diagnoses as contrasts. BASP1, brain abundant membrane-attached signal protein 1; BPD, bipolar disorder; LAMP, limbic system-associated membrane protein; SCZ, schizophrenia; STXBP1, syntaxin-binding protein 1.
synaptic membrane fusion, triggering the release of neurotransmitters into the synaptic gap. 54 Thus, our observation of increased STXBP1 could suggest a reduced syntaxin availability for SNARE complex assembly and a consequent reduction in neurotransmitter release. This, however, must be interpreted with some caution as the role of STXBP1 in the regulation of syntaxin and neurotransmitter release is incompletely characterized. 55 Several studies have examined syntaxin expression in SCZ and have demonstrated an increase in the mRNA level in the temporal cortex 56 and in protein levels in the cingulate cortex. 57, 58 However, no changes were reported in total syntaxin protein expression in the parietal cortex, 57 temporal cortex, 57 frontal cortex 57, 59, 60 or the cerebellum 61 in SCZ. Future studies would need to examine (i) the relationship of STXBP1 with syntaxin and SNARE complex formation as well as (ii) the expression of both proteins across several brain regions in SCZ.
BASP1 demonstrated significantly increased levels of expression in SCZ in the Stanley and Harvard subsample series and significantly increased levels in BPD in the Stanley subsample series when compared to controls. A single previous proteome study of unenriched SCZ dlpfc tissue concurs with our results in demonstrating increased BASP1 in SCZ. 16 Microarray studies by Fienberg's group observed a significant increase in BASP1 expression in the cerebellum of the SCZ brain. 62 BASP1 has been found previously in MM in the brain. 63 It is a cytoskeleton-associated, calmodulin-binding protein that is widely and abundantly expressed during brain development, maintained in selected brain structures in the adult and reinduced during nerve regeneration. 64 BASP1 is functionally related to GAP-43. Both proteins play a critical role in regulating neuritic outgrowth as well as the actin cytoskeleton and BASP1 can functionally substitute for GAP-43 in vivo. 64 Our results for BASP1 expression complement recent findings by Prabakaran et al. 16 who also demonstrated a > 2-fold increase in BASP1 expression in the white matter of schizophrenic brains. Interestingly, reductions in GAP-43 gene and protein expression have been reported in the SCZ and BPD brain. [65] [66] [67] Limbic system-associated membrane protein is characterized in this paper for the first time as a MM-associated protein. LAMP is a glycoprotein expressed on the surface of somata and proximal dendrites of neurons in cortical and subcortical regions of the limbic system. 68, 69 We found that LAMP demonstrated significantly increased levels of expression in SCZ and BPD in the Stanley subsample compared to controls. In the Harvard subsample, significant changes for both SCZ and BPD groups were not observed but percentage changes were of the same order as the Stanley subsample series. As for BASP1, LAMP is involved in mediating neuritic outgrowth and depending on the neuronal population, it can enhance or inhibit neurite outgrowth. 70 LAMP is expressed in limbic structures and has been implicated in SCZ 70, 71 by microarray studies, 72 which have shown a significant increase in its expression in the DLPFC in SCZ. 72 Neurite formation is a crucial stage in the development and plasticity of the neuron. We have shown LAMP, STXBP1 and BASP1 to be overexpressed in SCZ and BPD and these proteins have prominent roles in neurite formation and outgrowth. 64, 68 STXBP1, together with syntaxin 1, is involved in the regulation of SNARE-dependent membrane fusion for membrane expansion during neurite formation. 73 These results suggest that an altered circuitry, as a result of defective proteins that affect neurite formation and outgrowth, may be a component of the pathology of both SCZ and BPD. Several genes such as NRG-1, Akt1 and DISC have been shown to confer susceptibility for SCZ and proteins encoded by these genes are implicated in neurite formation in cellular and animal models of neurodevelopment. 74 In addition, the synaptic proteins VAMP-2 and SNAP-25 have demonstrated expression changes in SCZ and BPD and are also involved in neurite elongation and sprouting. 75 Further expression studies of proteins involved in neurite formation in these diseases are required to strengthen a hypothesis such as this. It is worth noting that previous expression studies in SCZ and BPD generally reported a tendency towards a reduced expression in SCZ and BPD, 76, 77 with increases in some synaptic-associated proteins, such as SNAP-25 60 and conflicting reports regarding other such as GAP-43 and synaptophysin. 37, [78] [79] [80] [81] [82] A strength of the current investigation is the use of two complementary proteomic approaches, 2D DIGE and GeLC-MS/MS to identify candidate diseaseassociated proteins within the MM proteome in SCZ and BPD. The use of these methods has allowed us to identify and then to proceed to validate important new disease-associated proteins within a functionally important but low-abundance proteome. Another major strength of the investigation is the extensive validation that we undertook to confirm the diseaseassociated protein changes. This involved undertaking validation experiments not just in a subsample of the Stanley Foundation Brain series, but also in a subsample of the Harvard McLean 66 Brain series. We confirmed protein changes in two independent brain series for STXBP1 and BASP1, which provides very strong evidence that the proteins STXBP1 and BASP1 are robust and worthy of further investigation in SCZ. We did not replicate our findings for the three proteins in BPD in the Harvard brain series. One possible explanation for this relates to the fact that our tissue samples were from different regions of the dlpfc and that region-specific differences in the expression of STXBP1, BASP1 and LAMP within the dlpfc could explain our loss of significance in the Harvard brain series. Further work is required to characterize the potential region-specific expression patterns of STXBP1, BASP1 and LAMP, in addition to clarifying the presence and nature of these protein changes in BPD and the expression of the LAMP protein in SCZ. As our validation criteria investigated those synaptic proteins altered in both SCZ and BPD, we did not pursue those equally interesting synaptic proteins NCAM, prohibitin and contactin. It is worth noting that our NCAM data complement previous findings that show NCAM to be increased in SCZ. 83 Future work by our group will examine the nature and extent of changes of these latter proteins in SCZ and BPD.
A potential limitation of the study is the use of pooled samples. However, it is increasingly accepted that validation of proteomic data is absolutely critical to acceptance and interpretation of findings. Consequently, it can be argued that where clinical samples are limited and precious, it is an efficient and valid strategy to undertake proteomic analysis of pooled clinical samples. This may allow identification of potential 'candidate' proteins, provided that extensive validation is undertaken on such proteins. Certainly in our case, our strategy has successfully identified proteins that, on validation, were confirmed as differentially expressed. In addition, we have validated candidate MM proteins, using whole and un-enriched dlpfc grey matter. As a result, we can conclude only that these MM proteins are differentially expressed in the cortex as a whole, and not necessarily in the MM specifically. Nonetheless, our findings of elevation of these proteins, regardless of their association with MM, provide evidence for synaptic and neuritic dysfunctions. Further studies would be required to investigate if STXBP1, BASP1 and LAMP are present within MM only or in both the MM fraction and the rest of the plasma membrane.
All post-mortem brain investigations are potentially confounded by the effects of duration of post-mortem interval and tissue pH. Therefore, we were careful to select our patient subsamples such that they were closely matched for these variables. Exposure to psychotropic medications can also influence protein expression differentially between disease and control groups. To account for these potential effects we examined, in both the Stanley and the Harvard brain series, the influence of neuroleptic agents, mood stabilizers and antidepressant medications, prescribed at the time of death, on protein expression. In the Stanley subsample, no significant differences in the protein expression of LAMP, STXBP1 or BASP1 was found between patients, in the SCZ and the BPD groups, who were prescribed these drugs compared with those who were not. However, in the Harvard subsample, significant reductions in BASP1 and STXBP1 protein expression were observed among those exposed to mood stabilizers. As the direction of this change was opposite to that associated with SCZ and BPD, this data and indeed the data as a whole provide no evidence that our observations of increases in protein expression of BASP1, STXBP1 or LAMP in these disorders are a consequence of drug treatments. To date, expression of several synaptic proteins following atypical antipsychotic drug treatment in the rat hippocampus has been investigated. 84 Trifluoperazine decreases synaptophysin expression within the hippocampal CA1 subregion, while haloperidol and CPZE increase SNAP-25 expression throughout the hippocampus. Haloperidol treatment has also been shown to upregulate synaptophysin mRNA in the striatum and frontoparietal cortex. 85 There is no animal literature assessing the influence of psychotropic medications on the expression of LAMP, STXBP1 or BASP1 specifically within the mammalian brain. Future studies should aim to clarify in detail the influence of psychotropic agents, particularly mood stabilizers, on synaptic-and neuritic-associated proteins that are also involved in neuronal plasticity.
To conclude, our observed changes in STXBP1, BASP1 and LAMP protein expression provide strong support for a substantial neurite pathology in the dlpfc in SCZ.
